Co-Diagnostics Inc

NASDAQ CODX

Data sourced from iex and EODHD
Download Data

Co-Diagnostics Inc Tangible Book Value per Share 5 year CAGR for the Trailing 12 Months (TTM) ending June 30, 2023

Co-Diagnostics Inc Tangible Book Value per Share 5 year CAGR is NA for the Trailing 12 Months (TTM) ending June 30, 2023. Tangible book value per share represents the shareholders' equity (tangible) minus goodwill and intangible assets divided by the weighted average number of outstanding shares. It provides the value of tangible assets per share owned by the shareholders. This ratio helps investors assess the tangible asset value relative to the number of shares outstanding. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Co-Diagnostics Inc Tangible Book Value per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was 1.80, a 1.63% change year over year.
  • Co-Diagnostics Inc Tangible Book Value per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was 1.77.
NASDAQ: CODX

Co-Diagnostics Inc

CEO Mr. Dwight H. Egan
IPO Date July 12, 2017
Location United States
Headquarters 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109
Employees 155
Sector Healthcare
Industry Medical devices
Description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Similar companies

CLPT

Clearpoint Neuro Inc

NA

NA

SRDX

SurModics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email